Background: Definitions of trial measures are consequential to accurately capturing outcomes and cross-trial comparability, particularly for derivative measures.
Objective: Using CombiRx, examine the impact of relapse definition on endpoints and evaluate the durability of progression measures in Relapsing Remitting Multiple Sclerosis (RRMS).
Methods: CombiRx relapse types were distinguished by the presence or timing of Expanded Disability Status Scale (EDSS) increase. Using the broadest definition of relapse, progression endpoints were assessed in patients without relapses on trial. Durability compared EDSS at study end and time of worsening.
Results: Broadening relapse definition to the most inclusive definition increased annualized relapse rate (ARR) threefold in all arms and decreased progression independent of relapse activity (PIRA), defined as 6-month confirmed disability worsening (6M CDW) without relapse, by 44%. Neither PIRA nor PIA (progression independent of any inflammatory activity) guaranteed durable worsening, with 43% and 40%, respectively, improving by end of study. Multivariate analysis showed two CDW events, not relapse, predicted durability among patients meeting 6M CDW.
Conclusions: The stringency of relapse definition impacted absolute ARR and composite endpoints in RRMS. Despite the most generous relapse definition, 43% of patients meeting PIRA on trial did not have durable worsening suggesting that relapse definition and durability should be considered to avoid overestimating progression in RRMS trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471316 | PMC |
| http://dx.doi.org/10.1177/13524585231157211 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rare histopathological diagnosis of malakoplakia and Rosai‑Dorfman disease in the same uterus mimicking malignancy: A case report.
Exp Ther Med
February 2025
Department of Histopathology, Specialty Hospital, Amman 11194, Jordan.
In the present case, a 66-year-old woman presented to the Specialty Hospital (Amman, Jordan) with recurrent post-menopausal bleeding. A pelvic ultrasound scan showed an abnormal endometrial thickness of 8 mm and no adnexal masses. An endometrial biopsy revealed abundant foamy histiocyte infiltration features suggestive of xanthogranulomatous endometritis.
View Article and Find Full Text PDFCurrent status and therapeutic value of extended pelvic lymph node dissection during radical prostatectomy for prostate cancer.
Prostate Int
September 2024
Division of Urology, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan.
Pelvic lymph node dissection (PLND) is important for accurate staging and prognosis of prostate cancer. Several guidelines recommend extended pelvic lymph node dissection (ePLND) for patients with non-low-risk prostate cancer. However, the therapeutic benefits of ePLND are unclear.
View Article and Find Full Text PDFGastric duplication cysts with mixed hemangioma treated by endoscopic submucosal dissection: A case report and literature review.
Pathol Res Pract
January 2025
Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong 262000, PR China. Electronic address:
Gastric duplication cysts (GDCs) are rare cystic neoplasms that are often difficult to distinguish from other entities. Accurate diagnosis of cysts before resection is difficult even using the most advanced imaging techniques. We present a case of a gastric duplication cyst in a 17-year-old female, presenting with discomfort in the upper abdomen.
View Article and Find Full Text PDFReal-world comparative outcomes and toxicities after definitive radiotherapy using proton beam therapy versus intensity-modulated radiation therapy for prostate cancer: a retrospective, single-institutional analysis.
J Radiat Res
January 2025
Department of Radiation Oncology, Southern Tohoku Proton Therapy Center 7-172, Yatsuyamada, Koriyama, Fukushima 963-8052, Japan.
This retrospective study aimed to compare the clinical outcomes of intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT). A total of 606 patients diagnosed with prostate cancer between January 2008 and December 2018 were included. Of these patients, 510 received PBT up to a dose of 70-78 Gy (relative biological effectiveness) and 96 patients received IMRT up to a dose of 70-78 Gy.
View Article and Find Full Text PDFConstruction of a prognostic model for gastric cancer based on immune infiltration and microenvironment, and exploration of MEF2C gene function.
BMC Med Genomics
January 2025
Department of Oncology, The First People's Hospital of Yibin, No.65, Wenxing Street, Cuiping District, Yibin, 644000, China.
Background: Advanced gastric cancer (GC) exhibits a high recurrence rate and a dismal prognosis. Myocyte enhancer factor 2c (MEF2C) was found to contribute to the development of various types of cancer. Therefore, our aim is to develop a prognostic model that predicts the prognosis of GC patients and initially explore the role of MEF2C in immunotherapy for GC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!